بسم الله الرحمن الرحيم

1. بسم الله الرحمن الرحيم

2. T. J. A IS STRONG PROPENSITY FOR T. E COMPLICATION THAT IS POTENTIALLY LIFE - THREATENING DVT

3. OBESITY CANCER PREVIOUS VTE FAMILY HISTORY SMOKING ADMISSION TO ICU DEHYDRATION THROMBOPHILIA CONTRACEPTIVE USE POST- OPERATION IMMOBILITY RISK- FACTORS

4. CHARNLEY & CO: 7959 CASES OF T. J. A 1962- 73 P- E : 8% FATAL CONDITION: 1% INSALL INCREASE ATTENTION TO T. E DISEAS AND EMPHASIS PREVENTION

5. DVT WITHOUT ANY PREVENTION 84%CLINICALLY P. E 1.7%FATAL P. E: - POSITIVE VENOGRAPHY NOT ITSELF ASSOCIATED WITH LOCAL SYMPTOMS

6. PRESENTATION OF T. E DISEASE FOLLOWING T. H. A & T. K. A IS DIFFERENT RELATED TO VIRCHOW’S TRIAD STASIS INTIMAL INJURY HYPERCOAGULABILITY

7. BEFORE ROUTINE USE OF CHEMOPROPHYLAXIS PROXIMAL DVT WAS IN 50- 60% OF T. H. A DISTAL WAS IN T. K. A

9. PROXIMAL THROMBI ALMOST IS SEGMENTAL AND NEAR LESSER TROCH LARGE MORE EMBOLIZE GREAT HEMODYNAMIC IMBALANCE MORE P. E RESULT

10. RESULT OF INTIMAL DAMAGE TO FEMORAL VEIN WHICH IS TWISTED DURING POSITION OF L- L PREPARATION & DEVICE INSERTION

11. POTENT ANTICOAGULANTS MITIGATE INTIMAL INJURY & REDUCE PROXIMIL THROMBI IN T. H. A DISTAL THROMBI AFTER T. K. A IS MORE RELATED TO BLOOD STASIS 1- FOLDING 3- OCCLUSION TOURNIQUET & ANTIGOAGULANT AND IPC ALONE ARE NOT EFFECTIVE IN PREVENTION OF POPLITEAL VEIN

12. PREVENTION WITH IPC AND REGIONAL ANESTHESIA OR IPC + CHEMOPROPHYLAXIS

13. RELEAS OF THE TOURNIQUET AFTER T. K. A TRANSESOPHAGEAL ECHOCARDIOGRAPHY HAS NOISE IN ECHO PATTERN FROM: 1- EMBOLIC 2- BONE MARROW 3- ELMENTS FAT

15. FAT FROM AFTER INTRAMEDULLARY CANAL INTRAVASATION CANAL PREPARATION PRESSURIZATION ON STEM CEMENTATION

16. ORTHOPEADIC SURGEON EMPHASIS TO: 1- PROPHYLAXIS OF CLINICAL EVENTS 2- BALANCE THE RISK OF BLEEDING MORE THAN: PREVENTION OF VENOGRAPHIC DISEASE

17. AMERICAN COLLEGE OF CHEST- PHYSICIAN (ACCP) SUGESST THAT ANTICOAGULANT NEEDED AS SOON AS ELEVATED BLEEDING RISK SUBSIDE

18. REGIONAL ANESTHESIA REDUCE DVT VASODILATATION BETTER VENOUS RETURN RESEMBLE OF SYMPATHECTOMY NO EFFECT ON INTRAOPERATIVE THROMBOGENIE BUT VASODILATION STIMULATE OF INTIMAL FIBRINOLYSIS PREVENTION OF DVT SPINAL EPIDURAL PROXIMAL CLOT 50% DISTAL CLOT 20%

19. 2- PNEUMATIC COMPRESSION: - I. P. C ALONE IS NOT VERY EFFECTIVE - I. P. C & REGIONAL ANESTHESIA HAS SYNERGIC EFFECT TO PREVENT OF DVT

20. WESTRICH & COLLEAGUES SUGGEST IPC AND HEPARIN REDUCE DVT THAT SIGNIFICANTLY BETTER THAN WARFARIN OR ASPIRIN

21. 3- ASPIRIN OVERALL ANTIPLATELER ARE INEFFECTIVE ON THE VENOUS SIDE OF CIRCULATION

22. RESULT OF STUDY IN 12291 PATIENT WITH T. J. A THAT ANALYSIS MORTALITY AT 1-6W 2- 3 MON G:A L. MW. H- XIMELAGTRAN - FONDAPARINUX G:B REGIONAL ANESTHESIA WITH OR WITHOUT 1- HEPARIN 2- IPC 3- ASPIRIN G: C WARFARIN

23. EMPHASIS THAT MULTIMODAL ASPIRIN PROPHYLALY IS BETTER ASPIRIN: REDUCE P. E. (CLINICAL MANIFESTATION OF V.T) SPECIALLY USE WITH REG- ANES

24. ACCORDINGLY: THERE IS BOTH EVIDENCE AND MOMENTUM GROWING TO JUSTIFY A RANDMIZED CLINICAL TRIAL COMPARING ASPIRIN – WARFARIN AND NEWER AGENT IN CONJUCTION WITH REG – ANES FOR VT PROPHYLAXIS AFTER T. J. A

25. SYMPTOMATIC & FATAL P. T. E IS MORE IN T. H. A THAN T. K. A RESIDUAL VENOGRAPHIC PREVALANCE OF DVT HAS BEEN MORE AFTER T. K. A CHMOPROPHYLAXIS

26. THIS MEAN THAT PREVENTION OF DVT AFTER T. K. A IS MORE REFRACTORY TO BOTH TRADITIONAL AND CONTEMPORARY DRUG PROPHYLAXIS

27. L. M. W. H OR FRACTIONAL MORE BINDING TO ANTI- THROMBIN III THAN CONVENTIONAL HEPARIN SO MORE EFFECT TO DVT PREVENTION IN T. J. A

28. HEPARIN INDUCED THROMBOCYTOPENIA (HIT) AND DEVASTING COMPLICATION OF ALL FORM OF HEPARIN UNCOMMON 2.6 % IN CONVENTIONAL- H 0.2 % IN L. M. W. H

29. FONDAPARINUX IS SYNTHETIC PENTASACCHARIDE BIND ONLY TO THE ANTI - THROMBIN III HEPARIN SITE AND HAD NO RISK OF HIT

30. ENOXAPARIN PROPHYLAXIS POWER, REDUCE V.T RATES FROM 28% TO 6%

31. RIVAROXABAN IN 2011 APPROVED BY FOOD & DRUG ADMINISTRATION REDUCE OVERALL DVT & ALL CAUSE MORTALITY. RATE UNDER 7% (IN 3148 T. K. A) 31.4% REDUCTION COMPARED WITH ENOXAPARIN

32. RIVAROXABAN 1- NEED NO MONITORING 2- METABOLIZE IN LIVER 3- ONLY ORAL USE 4- 10 mg DAILY 5- NO BLEEDING EVIDENT MORE THAN ENOXAPARIN

33. V. T OF CALF MANAGE WITH 6 WEEKS PERIOPERATIVE OF WARFARIN • PROXIMAL DVT WITH 12 WEEK WARFARIN • P. E WITH 3- 6 MONTHS • THERAPEUTIC (INR 2- 3) WARFARIN AFTER INITIAL ANTICOAGULATION WITH L. M. W. H MORE RECENTLY IN THE ERA OF L. M. W. H, IMMEDIATE OUTPATIENT TREATMENT OF V. T HAS BECOME POPULAR TREATMENT

34. HOW EVER, IN POSTOPERATIVE PATIENT WITH A SBSTANTIAL ATTENDANT RISK OF BLEEDING, INITIATION OF ANTICOAGULATION AS AN INPATIENT FOLLOWED BY OUT PATIENT THERAPY AFTER ANTICOAGULANT DOSING AND INTENSITY HAVE BEEN STABILIZED IS A MORE PRUDENT APPROACH

35. JBJS 2013/ 1/1 15670 T. J. A 5- YEAR 90 DAY FOLLOWED NO DIFFERENCE BETWEEN ASPIRIN AND L. M. W. H IN: T. E COMPLICATION P. E MORTALITY CONFIDENCE INTERVAL MAJOR HEMORROGE

36. COMBINED MECHANICAL & DRUG FOR 10- DAY AFTER T. K. A IS MORE EFFECTIVE

37. MORE PATIENT OF ASPIRIN GROUP MORE RETURN TO THEATER FOR WOUND COMPLICATION

38. CHARNLEY & CO 2012 7959 T. J. A 11 YEARS 1- PE: 8% 2- FATAL CASES 1% IN T. J. A WITHOUT PROPHYLAXIS DVT 84% CLINICALLY P.E 1.7% FATAL CASE OVERALL: IPC + L. M. W.H IS BETTER OF IPC + ASPIRIN OR WARFARIN

39. با تشكر از توجه شما